ArticleNature2021
Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 858 papers.
0numbers the graph read from it
0cells of the map it votes in
858citing papers in PubMed
72.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
858 citing papers in PubMed, 1,283 citations in OpenAlex.
- Article
- Virtual screening and experimental validation of a METTL3-targeting peptide withJournal of enzyme inhibition and medicinal chemistry · 2026Article
- The role of RNA modifications in cancer translational control.RNA biology · 2026Review
- Immunogenic cell death: synergizing ferroptosis and cuproptosis to overcome immunotherapy resistance.Medical oncology (Northwood, London, England) · 2026Review
- SEC Mediates mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- m6A methylation in ferroptosis regulation: mechanisms, targets, and therapeutic interventions.Journal of advanced research · 2026Review
- METTL3 promotes neutrophil extracellular trap formation via SYK/ERK/MEK signaling during acute lung injury.Journal of advanced research · 2026Article
- RNA mActa pharmacologica Sinica · 2026Review
- The cellular landscape of druggable RNA-binding proteins.Nature reviews. Drug discovery · 2026Review
- RNA therapeutics: current status and future directions.Signal transduction and targeted therapy · 2026Review
- Epigenetic Regulation of Ferroptosis in Inflammation: Molecular Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- METTL3 promotes human coronavirus replication through an interferon-independent mechanism.bioRxiv : the preprint server for biology · 2026Article
- Development of m6A Readers for Enhanced Recognition In Vitro via Genetic Code Expansion.ACS chemical biology · 2026Article
- Mutant KRAS-mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Maternal methionine supplementation regulates skeletal muscle development through NAnimal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Article
- RBM15 in leukemogenesis: an emerging regulator at the interface of RNA biology and hematopoiesis.Trends in cancer · 2026Review
- Role of the m6A methyltransferase Mettl16 in Drosophila development.PLoS genetics · 2026Article
- How Epitranscriptomic Machinery Senses Environmental Cues.Advanced biology · 2026Review
- Characterization of METTL3/14-mediated m6A modification in human transcriptome using Nanopore direct RNA sequencing.PLoS genetics · 2026Article
- The mitochondria enzyme OGDH defends against disulfidptosis by licensing METTL3-regulated NRF2 translation.Nature cell biology · 2026Article
798 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors at 6 institutions in 3 countries.
Eliza Yankova *Milner Therapeutics Institute, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-2913-0012
Wesley Blackaby *Storm Therapeutics Ltd, Cambridge, UK.
Mark AlbertellaStorm Therapeutics Ltd, Cambridge, UK.
Justyna RakHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.
Etienne De BraekeleerHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.
Georgia TsagkogeorgaMilner Therapeutics Institute, University of Cambridge, Cambridge, UK.
Ewa S PilkaEvotec (UK) Ltd, Abingdon, UK.ORCID http://orcid.org/0000-0002-0107-2597
Demetrios AsprisHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.
Dan LeggateStorm Therapeutics Ltd, Cambridge, UK.
Alan G HendrickStorm Therapeutics Ltd, Cambridge, UK.ORCID http://orcid.org/0000-0002-8604-0462
Natalie A WebsterStorm Therapeutics Ltd, Cambridge, UK.
Byron AndrewsStorm Therapeutics Ltd, Cambridge, UK.
Richard FosbearyStorm Therapeutics Ltd, Cambridge, UK.
Patrick GuestStorm Therapeutics Ltd, Cambridge, UK.
Nerea IrigoyenDivision of Virology, Department of Pathology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-6346-3369
Maria EleftheriouMilner Therapeutics Institute, University of Cambridge, Cambridge, UK.
Malgorzata GozdeckaHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.
Joao M L DiasMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.ORCID http://orcid.org/0000-0002-8451-3537
Andrew J BannisterThe Gurdon Institute and Department of Pathology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-6312-4436
Binje VickResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.ORCID http://orcid.org/0000-0003-1956-2778
Irmela JeremiasResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.ORCID http://orcid.org/0000-0003-1773-7677
George S VassiliouHaematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0000-0003-4337-8022
Oliver RauschStorm Therapeutics Ltd, Cambridge, UK. oliver.rausch@stormtherapeutics.com.ORCID http://orcid.org/0000-0003-4074-3848
Konstantinos TzelepisMilner Therapeutics Institute, University of Cambridge, Cambridge, UK. kt404@cam.ac.uk.ORCID http://orcid.org/0000-0002-4865-7648
Tony KouzaridesMilner Therapeutics Institute, University of Cambridge, Cambridge, UK. t.kouzarides@gurdon.cam.ac.uk.ORCID http://orcid.org/0000-0002-8918-4162
University of Cambridge · GBWellcome/MRC Cambridge Stem Cell Institute · GBHelmholtz Zentrum München · DEWellcome Sanger Institute · GBEvotec (United Kingdom) · GBMission Therapeutics (United Kingdom) · GB
Funding
Cancer Research UK 17001Cancer Research UK 23015Cancer Research UK 27321Cancer Research UK A17001European Research Council 268569European Research Council 681524Medical Research Council MC_PC_17230Wellcome Trust 210926Wellcome Trust 210926/Z/18/Z
Abstract
N
Indexed as
AdenosineAnimalsAntineoplastic AgentsApoptosisCell DifferentiationCell Line, TumorFemaleGene Expression Regulation, LeukemicHumansLeukemia, Myeloid, AcuteMethyltransferasesMiceMice, Inbred C57BLMolecular StructureXenograft Model Antitumor AssaysAdenosineAntineoplastic AgentsMethyltransferasesMETTL3 protein, humanMettl3 protein, mouseN-methyladenosine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.